Neurotoxic oligomers

Details Neurotoxic oligomers Neurotoxic oligomers

2001-06-28

2009-11-17

Kemmerer, Elizabeth C. (Department: 1649)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C530S300000, C530S328000

Reexamination Certificate

active

07618634

ABSTRACT:
This invention relates to methods and compositions for the treatment or alleviation of Alzheimer's disease and of other conditions related to abnormal protein aggregation. In particular, the invention relates to methods and compositions for the immunotherapy of Alzheimer's disease, Parkinson's disease, and cataract. In one aspect the invention provides a method of prophylaxis, treatment or alleviation of a condition characterized by pathological aggregation and accumulation of a specific protein associated with an immunizing-effective dose of one or more tyrosine cross-linked compounds, and optionally also comprising copper ions complexed to the compound. Alternatively passive immunization against a tyrosine cross-linked compound may be used. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.

REFERENCES:
patent: 4863735 (1989-09-01), Kohn et al.
patent: 5688651 (1997-11-01), Solomon
patent: WO 9927944 (1999-06-01), None
Schenk et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse, Nature, vol. 400, 1999, pp. 173-177.
Atwood et al. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem May 22, 1998; 273(21):12817-26.
Galeazzi et al. In vitro peroxidase oxidation induces stable dimers of beta-amyloid (1-42) through dityrosine bridge formation. Amyloid Mar. 1999 6(1):7-13.
Vickers. A vaccine against Alzheimer's disease: developments to date. Drugs Aging 2002; 19(7):487-94.
Perez et al. The beta-amyloid precursor protein of Alzheimer's disease enhances neuron viability and modulates neuronal polarity. J Neurosci. Dec. 15, 1997 ;17(24):9407-14.
Liu et al. Amyloid beta peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc Natl Acad Sci U S A. Oct 27 27, 1998;95(22):13266-71.
Casadesus et al. The estrogen myth: potential use of gonadotropin-releasing hormone agonists for the treatment of Alzheimer's disease. Drugs in R&D, 2006; 7(3):187-193.
Jacob J.S. et al., “Human Phagocytes Employ the Myeloperoxidase-Hydrogen Peroxide System to Synthesize Dityrosine, Trityrosine, Pulcherosine, and Isodityrosine by a Tyrosyl Radical-Dependent Pathway”,The Journal of Biological Chemistry, 271(33):19950-19956 (1996).
Souza J.M. et al., “Dityrosine Cross-Linking Promotes Formation of Stable α—Synuclein Polymers”,The Journal of Biological Chemistry, 275(24):18344-18349 (2000).
McLean C.A. et al., “Soluble Pool of Aβ Amyloid as a Determinant of Severity of Neurodegeneration in Alzheimer's Disease”,Annals Neurolgy, 46(6):860-866 (1999).
Hock C. et al., “Cerebrospinal Fluid Levels of Amyloid Precursor Protein and Amyloid β—Peptide in Alzheimer's Disease and Major Depression-Inverse Correlation with Dementia Severity”,Eur. Neurol, 39:111-118 (1998).
Atwood C.S. et al., “Role of Free Radicals and Metal Ions in the Pathogenesis of Alzheimer's Disease”,Metal Ions in Biological Systems, 36:309-364 (1999).
Kato Y. et al., “Immunohistochemical Detection of Dityrosine in Lipofuscin Pigments in the Aged Human Brain”,FEBS Letters, 439:231-234 (1998).

Affiliated with

Also associated with

Rating

Neurotoxic oligomers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neurotoxic oligomers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neurotoxic oligomers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4138909